Drug Overdose Treatment — Safer Combo for Severe Agitation

Drug overdose treatment for severe agitation from methamphetamine and cocaine overdoses New overdose combination therapy using dexmedetomidine and naloxone, grounded in opioid overdose research and preclinical dexmedetomidine naloxone study data Discover safer overdose treatment options and fresh insights to improve cocaine overdose management and methamphetamine intoxication agitation care What You'll Learn: How severe agitation in methamphetamine and cocaine intoxication complicates traditional drug overdose treatment and emergency department care Why dexmedetomidine’s ~65% reduction in sympathetic outflow (without lowering minute ventilation) may offer advantages over benzodiazepines for stimulant-related agitation Key pharmacology of naloxone, including its 2–3 minute onset, ~60-minute half-life, and implications for monitoring patients for re-sedation after opioid reversal What the Marshall University preclinical dexmedetomidine naloxone study found about survival benefits in polysubstance overdose models—and why the survival claim still needs peer verification How overdose combination therapy could change the management of methamphetamine intoxication agitation, cocaine intoxication agitation, and mixed opioid–stimulant presentations Practical bedside considerations for using dexmedetomidine and naloxone together, including airway safety, hemodynamic monitoring, and avoiding respiratory depression Limitations of current cocaine overdose management and opioid overdose research, and how future clinical trials might validate or refute the preclinical findings How to critically appraise emerging overdose research so you can separate promising ideas from preliminary animal data before changing practice About the Guest: About the Guest: This episode features researchers from Marshall University, including Michael Hambuchen, PharmD, PhD, from the Marshall University School of Pharmacy, and Todd Davies, PhD, from the Joan C. Edwards School of Medicine. Their work focuses on innovative pharmacologic strategies for managing severe agitation and respiratory compromise in complex drug overdoses, with a particular emphasis on polysubstance use involving opioids and stimulants.